Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Restructured By A Planned Reverse Merger

LATEST developments in the planned reverse merger. uni-Pharma distributing and Provista diagnostics researching, developing, and commercializing NEW GENERation of onko-SUre/dR-70 with the combination of DR-70 and Provista DX Biomarkers......

Here is the plan for new generation DR-70....

from 2/18/15 (still onko-sure)

The company has made at the end of 2014 Onko-Sure DR-70 tumor markers domestic production license, and earlier this year the domestic sales of the exhibition ? business plans within three years to complete major Asia-Pacific countries (Japan, Korea, Australia, New Zealand, ASEAN countries, China to Turkey and more than twenty countries) of the market, taken the domestic market into the regional market and even the size of the global market.
Arima drugs combined with a number of expert consultants and research units, using the latest technology to Onko-Sure DR-70 continuous improvement, expect the development of a second generation of rapid screening products or more precisely the Bead Assay products, but also about Arima binding Onko- the third generation of research reagents Sure combo with other tumor markers, the future will have an exclusive patent protection for these products are made and exclusive.

http://uni-pharma.com/news_detail-4.html

from 4/8/15 (oncoresult, see pics)

Turkey OnkoResult (Pharmaline subsidiary) in the past two to three years to implement DR-70 clinical trials, the results exceeded expectations, supported by many local doctors and teaching hospitals; April in particular to the company to visit, distributor negotiated issues, will actively Government budget execution for people tracking and screening program for colorectal cancer, and gradually applied to other cancers, and help the company to promote the DR-70 to neighboring countries.

http://uni-pharma.com/news_detail-2.html

We are waiting for Provista diagnostics and their breast Cancer studies..

Provista Diagnostics, Inc. published Late-Breaking Publication only Abstract in conjunction with the 2015 ASCO Annual Meeting

NEW YORK, NY, June 3, 2015 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc. today announced that they published an Abstract, in conjunction with the 2015 ASCO Annual Meeting held May 29 - June 2th, 2015 in Chicago, Illinois.

http://globenewswire.com/news-release/2015/06/03/741935/10137237/en/Provista-Diagnostics-Inc-published-Late-Breaking-Publication-only-Abstract-in-conjunction-with-the-2015-ASCO-Annual-Meeting.html?parent=704437

Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol

https://clinicaltrials.gov/show/NCT02078570

Prospective-retrospective analysis of a novel blood-based combinatorial biomarker assay (liquid biopsy) in 859 patients to demonstrate the benefit of combining biomarker data with imaging to differentiate benign breast lesions from invasive breast cancer in women.

http://meetinglibrary.asco.org/content/152899-156

************************************************************

This is All The DD and Rebuttals with ALL of the facts and findings you will ever need to know in ONE Quick Link and Page;

Why Radient Pharmaceuticals Public Shell will be utilized for The Proposed LOI of 2010 to reverse Merge with Provista Diagnostics.


Due Diligence: Analysis on Facts and Findings.


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113814338


June 28, 2015

Jim This should clear up ALL spins about Radient/AMDL DX /Uni Pharma?GCDX/Provista etc.. Notice the Circle R in Dr-70? You better you bet..Have mercy have merger.DR-70 .ahooooooooooooooooo

http://www.onkoresult.com.tr/


https://www.facebook.com/onkoresult/info?tab=overview


http://www.onkoresult.com.tr/dr-70.html

http://www.onkoresult.com.tr/10_soruda_dr-70.html



The agreement covers the following territories: China, Hong Kong, Malaysia, Singapore, Indonesia, Thailand, Japan, India, Turkey and Australia and New Zealand. We also agreed not to issue exclusive rights to any other person(s) to sell the Tests in the covered territories during the term of the agreement.



from 4/8/15 (oncoresult, see pics)

Turkey OnkoResult (Pharmaline subsidiary) in the past two to three years to implement DR-70 clinical trials, the results exceeded expectations, supported by many local doctors and teaching hospitals; April in particular to the company to visit, distributor negotiated issues, will actively Government budget execution for people tracking and screening program for colorectal cancer, and gradually applied to other cancers, and help the company to promote the DR-70 to neighboring countries.

http://uni-pharma.com/news_detail-2.html


FW: Our expansion with Onko-Sure happened almost by accident. Initially, we just wanted to distribute the product in Taiwan. We then began to develop within the region to markets like Singapore—but again, just as a distributor. However, we began to realize that we could do more.

There are multiple reasons for our evolution. Firstly, I think it was the right time. The company was looking for a new direction, and Onko-Sure had the right profile. With a pharmaceutical product, we would have had a hard time in Taiwan because of the challenges we would face in development and regulation. For diagnostic products, Taiwan has had significant strengths for at least ten years in OEM. By leveraging that history, and with the great partner that we have in Pharmigene, we can make great strides forward.

Taiwan is a small island. Every company has their unique strengths, but we need to team up in order to grow.


http://pharmaboardroom.com/interviews/interview-terry-lin-general-manager-and-freia-wei-senior-consultant-uni-pharma/


http://www.pharmigene.com/

Contact Info
United States

20112 Edinburgh Dr.,
Saratoga, CA 95070,USA

Tel: [phone]
Fax: [phone]

[e-mail]
Taiwan

4F., No. 17, Ln. 171, Sec. 2, Jiuzong Rd.,
Neihu Dist., Taipei City 114, Taiwan

Tel: [phone]
Fax: [phone]

[e-mail]


http://www.biotecheast.com/modules.php?op=modload&name=News&file=article&sid=2361&topic=2


GO Daddy.....

http://domain-kb.com/www/onkoresult.com

FACE BOOK.........
https://www.facebook.com/onkoresult


And a 5 Star review by the Wizard of OZ Turk you understand...ahooooooooooooooooooooooooooooooooooooooooo

https://www.facebook.com/mehmet.ozturk.98096

**************************************************

June 27, 2015

http://uni-pharma.com/

Just waiting for the triangular reverse merger you understand..

NEW WEB SITE Uni-Pharma...Selling Onko-Sure via AMDL Diagnostics Inc......The Monies keep flowing in you understand....ahoooooooooooooooooooooooooooooooooooo

http://uni-pharma.com/

All You Need to know about the upcoming and planned Reverse Merger in one DD Link..

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114020388


GetSeriousok..What you forgot to mention in your post and reply to livinginsv...The Radient/provista diagnostics lung cancer test will only cost 99 dollars, the competitors test even with government assistance will cost 599 dollars..Which do you think obamacare will choose and cover?


Reply to a gentlemen's bet for DC by livinginsv •Jun 4, 2015 6:06 PM

GetSeriousOK • Jun 4, 2015 6:12 PM

Living, you are stuck in a rut. The good ole US of A only has less than 5% of the world's population. The future is elsewhere (India and China) when it comes to Inexpensive Cancer treatment and testing procedures.
*****************************************************

Jim..we only own 4.99 per cent of the 4.5 billion outstanding RXPC shares, not what livinginsv suggested. lol...The angel investors own around 60 per cent, the lenders around 30 percent and DC and a few the other 5 per cent. That is a fact from a minority wolfpack ownership you understand.

Runncoach.. The reason there was no BK..Here is your answer..

http://www.sec.gov/Archives/edgar/data/838879/000114420412030793/v313941_8k.htm

Item 1.01 Entry Into a Material Definitive Agreement

Item 8.01 Other Events

As previously disclosed in our recent filings, we have been experiencing severe working capital shortages. In addition, substantially all of the holders of approximately $14.0 million of our notes and redeemable preferred shares (the “2011 Noteholders”) had previously declared defaults and demanded repayment of these obligations, which we were unable to pay.

On May 17, 2012, we completed an Agreement with the 2011 Noteholders, severally and not jointly, for the exercise of an aggregate of $150,000 worth of our Series A Common Stock Purchase Warrants at an exercise price of $0.02619 per share. The proceeds received from such Warrant exercise, shall be used solely and exclusively to enable us to keep our Registration Statement on Form S-1 filed under the Securities Act of 1933, as amended, which the Securities and Exchange Commission declared effective on February 14, 2012, current and maintain compliance with our reporting requirements under the Securities Exchange Act of 1934, as amended.



As a condition to the exercise of the Warrants, we agreed that following the date of the Agreement and through and including 5:00 p.m. (EDT) on August 31, 2012, we will not file in any U.S. Bankruptcy Court a voluntary petition for reorganization under Chapter 11 of Title 11 of the United States Code or seek to liquidate under Chapter 7 of such Code. Additionally, each of the 2011 Noteholders, severally and not jointly, agreed to forebear from exercising any of their rights and remedies, whether at law or in equity, against us and our current and former directors and officers for a period that shall not exceed the earlier to occur of (i) August 31, 2012, or (ii) a breach by us of any of our other covenants and agreements contained in the prior agreements with the 2011 Noteholders or in the current Agreement, including, without limitation, our commitment to file with the SEC our 2011 Form 10-K by June 30, 2012 and our March 31, 2012 Form 10-Q by July 15, 2012. The 2011 Noteholders further agreed that in the absence of a further breach of the terms of the Agreement or any of the other agreements between us and the 2011 Noteholders, that each of the previously issued default notices shall be deemed to be withdrawn ab initio upon execution of the Agreement.



Additionally, as part of the Agreement and in order to provide for payment of past due legal fees, we agreed to issue to our legal counsel, Hunter Taubman Weiss LLP, a $300,000 unsecured convertible 4% Company note payable on April 30, 2015, which shall (i) accrue interest at the annual rate of 4% per annum, (ii) be convertible into our Common Stock at a fixed conversion price of $0.01 per share, (iii) be subject to prepayment at the option of the Company, (iv) contain full ratchet and other customary anti-dilution protection, and (v) not be subject to any mandatory installment or other mandatory prepayment provisions prior to the April 30, 2015 maturity date.



http://www.sec.gov/Archives/edgar/data/838879/000114420411067784/v242030_8k.htm

http://www.sec.gov/Archives/edgar/data/838879/000114420411050187/v233664_8k.htm
***************************************************************
Radient Restructured By A Planned Reverse Merger

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114020388

You replied to getseriousok that is not true and correct..The web sites by the aussies are irrelevant. After the 2010 LOI reverse merger between radient and provista Diagnostics the NEW RADIENT web site will be this one.. http://provistadx.com/

Check out the news and archives...Hmmm guess what? BTW It would be illegal..You need to consult an attorney you understand...lol


livinginsv Wednesday, 06/03/15 02:04:48 PM
Re: Gold Seeker post# 29402
Post # of 29403


if the new BOD chooses to operate under the subsidiary AMDL, a private DE corp, and abandon the debt/equity burdened radient parent, there is nothing illegal about it . . .


Radient Restructured By A Planned Reverse Merger

May 26, 2015

The owner of the DR-70 federal registered trademark is AMDL Diagnostics Inc. An ongoing and Delaware Corporation in Good Standing and a wholly owned subsidiary of Radient Pharmaceuticals As you can see from the time table below...The owner at publication in 2010 would have been Radient Pharmaceuticals and not AMDL Inc. because the name change was already in effect in 2009. The change of address was made on February 20, 2013. This change was done 8 days prior to radient Pharmaceuticals going void on march 1, 2013.. Does AMDL Diagnostics Inc. own the rights to DR-70 Trademark and IP or radient, or a corporation named AMDL Inc.?

Why was the old Federal Trademark allowed cancelled in 2007...To only be reactivated with a new attorney and similiar tradename..From lower case Dd to upper Case D in the term DR-70?

https://trademarks.justia.com/754/14/dr-70-75414203.html

On 8/20/2009

AMDL Inc. , a US-based pharmaceutical company with major operations in China, announced the inauguration of AMDL Diagnostics Inc. (ADI), a new wholly-owned subsidiary that will focus on the research, development, manufacture and international sales of Onko-Sure(TM)-- AMDL's proprietary, regulatory approved in vitro diagnostic (IVD) cancer test.

http://www.biospace.com/News/amdl-inc-announces-inauguration-of-amdl/153720

On September 19, 2009

The Company has filed an amendment to its 'Articles of Incorporation' to implement this change effective prior to the open of the markets on Friday, September 25, 2009.

http://www.prnewswire.com/news-releases/amdl-inc-announces-stockholder-approval-of-name-change-and-issuance-of-a-new-trading-symbol-on-the-nyse-alternext-us-59727442.html


Trademark Events
Event Date
Event Description

2009-02-09 NEW APPLICATION ENTERED IN TRAM
2009-02-09 NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2009-04-23 ASSIGNED TO EXAMINER
2009-04-29 NON-FINAL ACTION WRITTEN
2009-04-29 NON-FINAL ACTION E-MAILED
2009-04-29 NOTIFICATION OF NON-FINAL ACTION E-MAILED
2009-05-28 TEAS REVOKE/APPOINT ATTORNEY RECEIVED
2009-05-28 ATTORNEY REVOKED AND/OR APPOINTED
2009-08-18 TEAS REVOKE/APPOINT ATTORNEY RECEIVED

2009-08-18 ATTORNEY REVOKED AND/OR APPOINTED

8/20/2009

AMDL Inc. , a US-based pharmaceutical company with major operations in China, announced the inauguration of AMDL Diagnostics Inc. (ADI), a new wholly-owned subsidiary that will focus on the research, development, manufacture and international sales of Onko-Sure(TM)-- AMDL's proprietary, regulatory approved in vitro diagnostic (IVD) cancer test.

AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major assets in China, announced today its stockholders have approved by verbal consent the name change and rebranding of the Company as "Radient Pharmaceuticals Corporation".
The Company has filed an amendment to its 'Articles of Incorporation' to implement this change effective prior to the open of the markets on Friday, September 25, 2009.

2009-10-27 TEAS RESPONSE TO OFFICE ACTION RECEIVED
2009-11-04 ASSIGNED TO LIE
2009-11-04 CORRESPONDENCE RECEIVED IN LAW OFFICE
2009-11-04 TEAS/EMAIL CORRESPONDENCE ENTERED
2009-12-02 NON-FINAL ACTION WRITTEN
2009-12-02 NON-FINAL ACTION E-MAILED
2009-12-02 NOTIFICATION OF NON-FINAL ACTION E-MAILED
2010-04-22 TEAS RESPONSE TO OFFICE ACTION RECEIVED
2010-04-22 CORRESPONDENCE RECEIVED IN LAW OFFICE
2010-04-23 TEAS/EMAIL CORRESPONDENCE ENTERED

2010-05-17 APPROVED FOR PUB - PRINCIPAL REGISTER

Party Name
AMDL, Inc.
Party Type
20 - Owner at Publication

2010-05-19 LAW OFFICE PUBLICATION REVIEW COMPLETED

2010-06-22 PUBLISHED FOR OPPOSITION
2010-06-22 OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2010-09-07 REGISTERED-PRINCIPAL REGISTER

2013-02-20 TEAS CHANGE OF CORRESPONDENCE RECEIVED

Radient Pharmaceuticals Corporation Void Delaware Corporation on March 1, 2013..



https://trademarks.justia.com/776/64/dr-70-77664344.html



***************************************************************

MAy 19, 2015

". if the current shareholders want their stock to be revived, they should e-mail charter with a cash offer . . ."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113816960

This is not true..The President and/or Secretary according to Delaware Corporation law.. mac and akio never resigned as president and secretary respectively..They can revive the Delaware Corporation. The aussies including Charter do not have that power of attorney to revive radient unless Mac and Akio were decease.If you can prove with FACTS that they resigned these positions, then your premise would be valid...Mac and Akio have control of radient and can revive the voided corporation at anytime....


Mr. MacLellan resigned as Chairman and CEO and Mr. Christiansen resigned as the Company's only other board member. Separately, Mr. Akio Ariura the Company's previous CFO and COO, resigned from both positions on April 28, 2014.

http://www.sec.gov/Archives/edgar/data/838879/000114420414027804/v377522_8k.htm

"If the last president and secretary or treasurer or the officers performing the functions of said offices or any of them of any such corporation so desiring to renew or revive its charter should be dead at the time of such renewal or should refuse or neglect to act with respect thereto as provided in the first paragraph of this section, the directors of such corporation or the survivors of them, if not less than three, may elect a successor to such officer or officers who are dead or refuse or neglect to act as aforesaid."

http://delcode.delaware.gov/sessionlaws/ga105/chp147.shtml

POWER OF ATTORNEY



ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Douglas C. MacLellan and Akio Ariura, or either of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K/A any documents related to this report and filed pursuant to the Securities Exchange Act of 1934, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Here is the SEC 8-K filing showing mac as president and Akio as secretary of radient Pharmaceuticals Inc.. They did not resign these positions in 2014.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.


Signature Title Date

/s/ Douglas C. MacLellan President, Chief Executive Officer, and Director July 9, 2012
DOUGLAS C. MACLELLAN (Principal Executive Officer)

/s/ Akio Ariura Chief Operating Officer, Chief Financial Officer July 9, 2012
AKIO ARIURA and Secretary (Principal Financial Officer and
Principal Accounting Officer)

/s/ Michael Boswell Director July 9, 2012
MICHAEL BOSWELL


http://www.sec.gov/Archives/edgar/data/838879/000114420412038691/v317969_10ka.htm


This is All The DD and Rebuttals with ALL of the facts and findings you will ever need to know in ONE Quick Link and Page;

Why Radient Pharmaceuticals Public Shell will be utilized for The Proposed LOI of 2010 to reverse Merge with Provista Diagnostics.


Due Diligence: Analysis on Facts and Findings.


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113814338